Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Relypsa, Inc. (RLYP), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in RLYP.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 3 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $2.15 a share a month ago to its current level of $2.79.
Also, for the current quarter, Relypsa has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 56 cents a share from 52 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 33.7% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the medical sector, you may instead consider some better-ranked stocks including Dr. Reddy's Laboratories Ltd. (RDY), Mallinckrodt plc (MNK) and Actavis plc (ACT). While Dr. Reddy’s and Mallinckrodt hold a Zacks Rank #1 (Strong Buy), Actavis carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
DR REDDY'S LAB LTD ADR (RDY): Free Stock Analysis Report
MALLINCKRODT PUBLIC LTD CO (MNK): Free Stock Analysis Report
ACTAVIS PLC NEW (ACT): Free Stock Analysis Report
RELYPSA INC (RLYP): Free Stock Analysis Report
Zacks Investment Research